4MO Updated results for MK-1084 + pembrolizumab in KRAS G12C-mutated (mut) metastatic non-small cell lung cancer (mNSCLC) enrolled in KANDLELIT-001

ESMO Open 2026 Open access

Read full text
Authors: A.G. Sacher, Yakir Rottenberg, M. Kwiatkowski, M.A.N. Sendur, O. Kobziev, T. Yoshida, L. Liu, C-C. Lin, Y-L. Su, I. Lugowska, A. Raskov Kodahl, I. Ruíz-Gutiérrez
+8 more G. Ursol, C.I. Rojas, J. Bar, Matteo Simonelli, L. Rhoda Molife, Thomas Jemielita, S.Y. Choi, Maya Gottfried
DOI: 10.1016/j.esmoop.2026.106311
Cited by: 3

Abstract

The phase I KANDLELIT-001 study (NCT05067283) showed manageable safety and promising antitumor activity for the oral, next-generation, selective KRAS G12C-GDP covalent inhibitor MK-1084 given as monotherapy or as part of combination therapy in participants (pts) with KRAS G12C-mut solid tumors. We report updated data for pts with KRAS G12C-mut mNSCLC.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Melanoma and MAPK Pathways

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106311–106311
Publication date
17 March 2026
Language
EN